Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE), 2025
ESPE-ESE 2025 10 - 13 May 2025

Weekly somapacitan is effective and well-tolerated in children born small for gestational age: randomized phase 3 trial

Authors :

Agnès Linglart1; Volker Böttcher2; Michael Højby3; Carlos Alberto Longui4; Joshua Smith5; Masanobu Kawai6
Affiliations
View Details Hide Details
{{ getPageNum(PDFPage) }}
Keywords
Rare Endocrine Disorder
Congress oral presentation
Somapacitan